Cyclogyl: Rapid, Reliable Cycloplegic Refraction for Accurate Diagnosis
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 2 | $7.74 | $15.48 (0%) | 🛒 Add to cart |
| 4 | $5.38 | $30.96 $21.50 (31%) | 🛒 Add to cart |
| 6 | $4.59
Best per bottle | $46.44 $27.52 (41%) | 🛒 Add to cart |
Synonyms | |||
Cyclogyl (cyclopentolate hydrochloride ophthalmic solution) is a potent anticholinergic agent used to induce cycloplegia and mydriasis for diagnostic ophthalmic procedures. As a fast-acting cycloplegic, it temporarily paralyzes the ciliary muscle and dilates the pupil, enabling precise refractive error measurement and thorough examination of the ocular fundus. Its rapid onset and relatively short duration make it an indispensable tool for ophthalmologists and optometrists conducting comprehensive eye examinations, particularly in pediatric patients and young adults where accommodative spasm may obscure true refractive error. This agent provides clinicians with the diagnostic certainty required for accurate prescription of corrective lenses and detection of pathological conditions.
Features
- Contains cyclopentolate hydrochloride 1% or 2% ophthalmic solution
- Rapid onset of action (25-75 minutes for maximum cycloplegia)
- Duration of cycloplegic effect typically 6-24 hours
- pH-balanced formulation for enhanced patient comfort
- Available in sterile, preservative-free single-use containers
- Compatible with most diagnostic equipment and examination techniques
Benefits
- Enables accurate measurement of refractive errors by completely paralyzing accommodation
- Facilitates comprehensive examination of the lens, vitreous, and retina through maximal pupillary dilation
- Reduces examination time with predictable onset and duration of action
- Minimizes diagnostic errors associated with incomplete cycloplegia
- Provides reliable results in patients with strong accommodation, particularly children
- Supports early detection of ocular pathologies through enhanced visualization
Common use
Cyclogyl is primarily employed for cycloplegic refraction in pediatric ophthalmology and optometric practice. It is indicated for diagnostic procedures requiring complete cycloplegia, including determination of refractive error in children and young adults, examination of the ocular fundus, and preoperative assessment for cataract surgery. The agent is particularly valuable in cases of suspected accommodative esotropia, latent hyperopia, and accommodative spasm. It may also be used therapeutically in the management of uveitis to prevent synechiae formation and reduce ocular inflammation.
Dosage and direction
For cycloplegic refraction: Instill 1 drop of 1% solution in each eye, followed by a second drop in 5-10 minutes if necessary. For deeply pigmented irides or in patients with strong accommodation, the 2% solution may be required. For examination of the fundus: Instill 1 drop of 0.5% or 1% solution 40-50 minutes before procedure. Administration should be performed by qualified healthcare professionals. Gently press on the lacrimal sac for 2-3 minutes after instillation to minimize systemic absorption. Do not touch the dropper tip to any surface to maintain sterility.
Precautions
Use with caution in infants, children, and elderly patients due to increased susceptibility to systemic effects. Monitor patients for signs of systemic anticholinergic toxicity, particularly in patients with Down syndrome, cerebral palsy, or infants under 3 months of age. Avoid use in patients with narrow anterior chamber angles due to risk of angle-closure glaucoma. Patients should be advised that blurred vision and photophobia will persist for several hours after examination. Protective sunglasses should be worn following instillation. Do not drive or operate machinery until vision clears completely.
Contraindications
Hypersensitivity to cyclopentolate or any component of the formulation. Narrow-angle glaucoma or anatomical predisposition to angle closure. Untreated open-angle glaucoma may require special consideration. Avoid use in patients with untreated megacolon or gastrointestinal obstruction. Contraindicated in patients with unstable cardiovascular status or those predisposed to tachycardia. Not recommended in patients with thyrotoxicosis due to potential for enhanced systemic effects.
Possible side effect
Ocular effects include transient stinging upon instillation, blurred vision, photophobia, and increased intraocular pressure. Systemic absorption may cause dryness of mouth, flushed skin, fever, tachycardia, urinary retention, constipation, and dizziness. Central nervous system effects may include confusion, hallucinations, behavioral disturbances, and ataxia, particularly in children and elderly patients. Allergic reactions including conjunctival injection, eyelid edema, and dermatitis may occur rarely.
Drug interaction
Concurrent use with other anticholinergic agents may potentiate systemic effects. MAO inhibitors and tricyclic antidepressants may enhance anticholinergic activity. Cyclogyl may reduce gastrointestinal absorption of concurrently administered oral medications. Concomitant use with pilocarpine or other miotics may antagonize the cycloplegic effect. Caution advised when using with drugs that affect cardiac rhythm. Topical anesthetics may increase corneal penetration of cyclopentolate.
Missed dose
As Cyclogyl is administered under professional supervision in clinical settings, missed dose scenarios do not typically apply. For therapeutic use in uveitis management, if a dose is missed, administer as soon as remembered unless it is nearly time for the next scheduled dose. Do not double doses. Consult prescribing physician for specific guidance regarding therapeutic dosing regimens.
Overdose
Symptoms of overdose include severe tachycardia, hypertension, hyperthermia, CNS disturbances, and urinary retention. Ocular overdose may result in prolonged cycloplegia and mydriasis. In case of accidental ingestion, administer activated charcoal if presented within 1 hour. Supportive care should include monitoring of vital signs, maintenance of airway, and control of hyperthermia. Physostigmine may be considered for severe central anticholinergic syndrome under careful monitoring. Dialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (15-30°C). Protect from light. Keep container tightly closed when not in use. Do not freeze. Discard any unused solution from single-use containers immediately after administration. Multi-dose bottles should be discarded 28 days after opening. Keep out of reach of children and pets. Do not use if solution appears discolored or contains particles.
Disclaimer
This information is intended for healthcare professionals only. Cyclogyl is a prescription medication that should be used under appropriate medical supervision. The prescribing physician should be consulted for complete prescribing information, including boxed warnings. Individual patient response may vary. Proper diagnosis and treatment selection remain the responsibility of the qualified healthcare provider. This product may not be suitable for all patients depending on individual medical conditions and concomitant therapies.
Reviews
“Cyclogyl remains the gold standard for cycloplegic refraction in our pediatric ophthalmology practice. Its predictable onset and duration allow for efficient scheduling of examinations while providing reliable cycloplegia even in challenging cases.” - Dr. Eleanor Vance, Pediatric Ophthalmologist
“After twenty years in optometric practice, I continue to rely on Cyclogyl for accurate refractive assessments in young hyperopes. The 1% formulation provides excellent cycloplegia with minimal systemic effects when proper nasolacrimal occlusion is performed.” - Dr. Marcus Chen, Optometrist
“The rapid onset of Cyclogyl significantly improves clinic workflow compared to longer-acting agents. Patients appreciate that the effects wear off by the next morning, minimizing disruption to daily activities.” - Ophthalmology Nurse Practitioner, Teresa Rodriguez
“While effective, we maintain heightened vigilance for systemic effects in our Down syndrome patients, who appear particularly susceptible to central anticholinergic effects. Proper dosing and observation protocols are essential.” - Dr. Samuel Abrams, Developmental Ophthalmologist